Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced positive data from a Phase 2 placebo-controlled study evaluating IONIS-FXIRx in patients with end-stage renal disease (ESRD) on …
Today, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Biogen Inc (NASDAQ:BIIB) announced the completion of a rolling submission of New Drug Application (NDA) to the …
Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals Inc (NASDAQ:IONS), announced the publication in The Lancet of key clinical results of two randomized, …
Wells Fargo maintains Outperform, while lifting the valuation range from $61 to $64 up to $63 to $68.
Piper Jaffray analyst Joshua Schimmer provides a 2H16 outlook for Ionis Pharmaceuticals Inc (NASDAQ:IONS) of what the analyst considers a “volatile year” for …
Valeant Pharmaceuticals Intl Inc Analyst Ram Selvaraju of Rodman & Renshaw was out with a research note on shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) …
Ionis Pharmaceuticals Inc (NASDAQ:IONS) posted second-quarter financial results and provided a clinical progress update. Despite many of the drug maker’s pipeline candidates continuing to make …
Ionis Pharmaceuticals Inc (NASDAQ:IONS) reported that its financial results for the first half of 2016 were in line with the Company’s expectations and …
Yesterday morning, California-based biopharm company Ionis Pharmaceuticals Inc (NASDAQ:IONS) made a positive stride with its clinical drug nusinersen, announcing that major motor milestones were achieved …
Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Biogen (NASDAQ:BIIB) announced that nusinersen, their investigational treatment for spinal muscular atrophy (SMA), met the primary endpoint pre-specified …
